Pfizer Inc. (NYSE:PFE) Stock Has Consensus Price Target of $28.39 According to Brokerages

Shares of Pfizer Inc. (NYSE:PFE) have earned an average rating of “Hold” from the twenty-one ratings firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, fourteen have assigned a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $28.39.

A number of research firms have recently issued reports on PFE. JPMorgan Chase & Co. cut their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. HSBC upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, September 10th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Finally, BMO Capital Markets reduced their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th.

Hedge Funds Weigh In On Pfizer

A number of large investors have recently made changes to their positions in the company. QRG Capital Management Inc. lifted its holdings in Pfizer by 5.8% during the 2nd quarter. QRG Capital Management Inc. now owns 902,308 shares of the biopharmaceutical company’s stock worth $21,728,000 after purchasing an additional 49,804 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in Pfizer by 16.0% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 179,745 shares of the biopharmaceutical company’s stock valued at $4,328,000 after buying an additional 24,744 shares in the last quarter. Envestnet Asset Management Inc. increased its position in Pfizer by 1.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 9,513,242 shares of the biopharmaceutical company’s stock worth $229,078,000 after buying an additional 167,641 shares during the period. Andra AP fonden lifted its holdings in shares of Pfizer by 196.6% during the second quarter. Andra AP fonden now owns 728,273 shares of the biopharmaceutical company’s stock worth $17,537,000 after buying an additional 482,700 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Pfizer by 1.8% in the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after acquiring an additional 5,501,032 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of PFE stock opened at $28.41 on Friday. The company has a fifty day moving average price of $26.98 and a two-hundred day moving average price of $26.41. Pfizer has a one year low of $23.58 and a one year high of $29.21. The stock has a market cap of $161.91 billion, a P/E ratio of 37.38, a P/E/G ratio of 1.88 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the firm earned $0.78 EPS. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts predict that Pfizer will post 2.98 EPS for the current year.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Updated COVID-19 vaccine could support seasonal revenue. The FDA approved Pfizer and BioNTech’s 2026–2027 COMIRNATY XFG formula, targeting the XFG variant for older adults and certain younger high-risk individuals. The approval provides another opportunity to generate post-pandemic vaccine sales, although demand remains substantially below pandemic-era levels. Could a New Vaccine Formula XFG Give Pfizer and BioNTech a Post-Pandemic Revenue Boost?
• Positive Sentiment: RSV expansion remains a potential growth driver. Pfizer completed a Phase 3 study in Japan evaluating its RSVpreF vaccine in adults. While efficacy and regulatory outcomes are still pending, success could broaden the vaccine’s international and adult-market opportunity. Pfizer’s Japanese RSV Vaccine Study Wraps Up, Expanding Adult Market Potential
• Positive Sentiment: Pipeline development and cost reductions support the longer-term case. Recent analysis highlights Pfizer’s newer medicines, business-development activity and cost-cutting program as possible offsets to declining COVID products and upcoming patent pressures. Pfizer: Poised For Gains With a New Drug Pipeline and Cost-Cutting Plans
• Neutral Sentiment: Analysts remain divided relative to AbbVie and Eli Lilly. Comparisons emphasize Pfizer’s restructuring, pipeline prospects, acquisitions and patent exposure, but do not identify a new company-specific earnings catalyst. Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
• Negative Sentiment: COVID revenue declines and valuation concerns remain overhangs. Commentary notes that Pfizer’s COVID products continue to shrink and overall revenue has been broadly flat, while another analysis argues the stock may already reflect benefits from an overseas pricing agreement. Pfizer Stock May Be Overvalued After Overseas Pricing Deal
• Negative Sentiment: High dividend yield raises payout-risk questions. Articles identify Pfizer as a high-yield stock with positive free cash flow but an unfavorable payout ratio, increasing investor sensitivity to earnings weakness and patent cliffs. Pfizer, Kraft, and UPS: Which Dividend Stock Is Safest?

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.